Physician profile
Farrah E Gardner
NPI 1477915569
$3,075.63
in general payments reported to CMS, 2019-2025
34 companies · $269 in 2025
The $269 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,418 · 2022: $353 · 2023: $497 · 2024: $538 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,304.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $652.96 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $407.07 | 2021-2025 | |
| Lilly USA, LLC | $356.62 | 2021-2024 | Mounjaro |
| Astrazeneca Pharmaceuticals Lp | $241.59 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $238.77 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $158.27 | 2021 | |
| Amgen INC. | $125.29 | 2021-2025 | Repatha, Evenity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.33 | 2021-2024 | Xifaxan |
| Novo Nordisk INC | $99.46 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $60.98 | 2021-2022 | |
| Amarin Pharma, INC. | $56.13 | 2021 | |
| Almatica Pharma LLC | $52.34 | 2021 | |
| Supernus Pharmaceuticals, INC. | $51.48 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $41.44 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.13 | 2024-2025 | Caplyta |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $36.60 | 2021 | |
| Novartis Pharmaceuticals Corporation | $33.85 | 2025 | |
| Sanofi-Aventis U.S. LLC | $32.30 | 2021 | |
| Exact Sciences Corporation | $30.46 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.58 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $24.43 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.58 | 2024 | |
| Ironshore Pharmaceuticals INC. | $19.63 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.61 | 2021 | |
| Redhill Biopharma INC. | $19.20 | 2021 | |
| Sanofi Pasteur INC. | $18.75 | 2023 | |
| Dexcom, INC. | $17.59 | 2023 | Dexcom G6 Transmitter |
| Lantheus Medical Imaging, INC. | $16.51 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.39 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.96 | 2021 | |
| Genentech USA, INC. | $15.79 | 2021 | |
| Acadia Pharmaceuticals INC | $15.44 | 2024 | Daybue |
| Adlon Therapeutics L.P. | $11.28 | 2021 | |
| Corium, LLC | $2.82 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farrah Gardner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.